European approval for Pfizer\'s Vizimpro in firstline nonsmall cell lung cancer

European approval for Pfizer's Vizimpro in first-line non-small cell lung cancer

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a first-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

Data derived from a Phase 3 study examining the drugs’ use in 227 patients with EGFR-mutated metastatic NSCLC showed a “statistically significant improvement” in progression-free survival, as determined by Independent Radiologic Central (IRC) review, meeting the primary endpoint.

read more

More From BioPortfolio on "European approval for Pfizer's Vizimpro in first-line non-small cell lung cancer"